Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mequitazine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Mequitazine. Displaying page 1 of 1.
    EudraCT Number: 2006-006165-17 Sponsor Protocol Number: L00013 CP 301 Start Date*: 2006-12-27
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: EFFICACY OF AN EARLY ADMINISTRATION OF L0013CP 10 MG/DAY VERSUS PLACEBO DURING 4 WEEKS IN THE TREATMENT OF INFECTIOUS DISEASES INDUCED ARTHRITIS PAINFUL SYMPTOMS. A MULTICENTER, RANDOMISED, DOUBLE ...
    Medical condition: CHIKUNGUNYA FEVER.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005975-13 Sponsor Protocol Number: V00114 CP 201 Start Date*: 2006-04-25
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis.
    Medical condition: Prospective, multicentric, international, randomised, double-blind trial in six parallel groups: 4 doses of the test product, active control and placebo. This study is intended to evaluate the ef...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001860-36 Sponsor Protocol Number: V00114CP3042A Start Date*: 2008-05-29
    Sponsor Name:Pierre Fabre Médicament
    Full Title: EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CO...
    Medical condition: The medical condition to be investigated in this study is the seasonall allergic rhinitis. The intendent indication for the product is the treatment of allergic rhinitis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-006947-30 Sponsor Protocol Number: V00114 CP 301 2A Start Date*: 2007-05-11
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: EFFICACY STUDY OF THE ANTIHISTAMINE V0114 CP 2.5MG TABLET IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Medical condition: ALLERGIC RHINITIS prospective, multicentric, international, randomised, double-blind trial in two parallel groups: V0114CP 2.5 mg tablet versus placebo. This study is planned to assess the effica...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) FR (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-024271-10 Sponsor Protocol Number: V00162GL203 Start Date*: 2011-07-06
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Urodynamic effect of one single vaginal application of 2 mL of V0162 gel (0.8%) in post-menopausal women with overactive bladder
    Medical condition: Overactive Bladder symptoms.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000133-22 Sponsor Protocol Number: V00114 CP 304 2A Start Date*: 2008-04-28
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Estudio de la eficacia y seguridad del antihistamínico V0114CP 2.5 mg en el tratamiento de la rinitis alérgica estacional. Estudio aleatorizado, doble ciego, de tres ramas y grupos paralelos, que i...
    Medical condition: Demostrar la eficacia de un tratamiento de 2 semanas con el antihistamínico V0114CP 2,5 mg frente a placebo en la reducción de síntomas de la rinitis alérgica estacional
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) EE (Completed) BE (Completed) LT (Completed) PL (Completed) HU (Completed) DE (Completed) IT (Completed) BG (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-003572-19 Sponsor Protocol Number: V00114 CP 302 2A Start Date*: 2007-12-04
    Sponsor Name:Pierre Fabre Médicament
    Full Title: EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF PERENNIAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIV...
    Medical condition: The intended indication for the product under development is the treatment of perennial allergic rhinitis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) LT (Prematurely Ended) CZ (Completed) GB (Prematurely Ended) ES (Completed) FI (Prematurely Ended) LV (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-008734-36 Sponsor Protocol Number: V00114CP3052A Start Date*: 2009-04-14
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: ESTUDIO DE LA EFICACIA Y SEGURIDAD DEL ANTIHISTAMÍNICO V0114CP 2,5 MG EN EL TRATAMIENTO DE LA RINITIS ALÉRGICA ESTACIONAL. ESTUDIO ALEATORIZADO, DOBLE CIEGO, DE TRES RAMAS Y GRUPOS PARALELOS, QU...
    Medical condition: Rinitis alérgica
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) LT (Prematurely Ended) DE (Prematurely Ended) PL (Completed) SK (Prematurely Ended) EE (Prematurely Ended) HU (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002517-35 Sponsor Protocol Number: V00162PI2024A Start Date*: 2013-09-05
    Sponsor Name:Pierre Fabre Médicament/Institut de Recherche Pierre Fabre
    Full Title: Bronchodilator properties and safety of a repeated dose of V0162 inhalation powder in asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: Removed from public view
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 08:21:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA